Published in Am J Gastroenterol on August 26, 2014
Optimizing biologic treatment in IBD: objective measures, but when, how and how often? BMC Gastroenterol (2015) 0.84
Promising biological therapies for ulcerative colitis: A review of the literature. World J Gastrointest Pathophysiol (2015) 0.81
Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials. Gut Liver (2016) 0.81
Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal. Gastroenterol Res Pract (2015) 0.79
Optimal management of steroid-dependent ulcerative colitis. Clin Exp Gastroenterol (2015) 0.79
Dose Escalation and Healthcare Resource Use among Ulcerative Colitis Patients Treated with Adalimumab in English Hospitals: An Analysis of Real-World Data. PLoS One (2016) 0.78
Inflammatory bowel disease surgery in the biologic era. World J Gastrointest Surg (2016) 0.77
Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study. Can J Gastroenterol Hepatol (2016) 0.76
Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis. Can J Gastroenterol Hepatol (2016) 0.75
Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease. Inflamm Bowel Dis (2017) 0.75
Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis. Gut Liver (2016) 0.75
Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol (2017) 0.75
Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation. Dig Dis Sci (2016) 0.75
Tacrolimus versus anti-tumor necrosis factor agents for steroid-refractory active ulcerative colitis based on the severity of endoscopic findings: a single-center, open-label cohort study. Clin Exp Gastroenterol (2017) 0.75
The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics (1993) 7.19
Ulcerative colitis. N Engl J Med (2011) 6.14
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut (2011) 6.08
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology (2011) 5.38
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet (2009) 5.03
Ulcerative colitis. Lancet (2012) 3.38
Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology (1994) 3.22
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol (2010) 2.74
Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis (2012) 2.29
Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm Bowel Dis (2009) 1.30
One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther (2012) 1.24
The role of TNFalpha in ulcerative colitis. J Clin Pharmacol (2007) 1.20
52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis (2013) 1.16
Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology (2013) 1.12
Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review. J Gastroenterol Hepatol (2013) 0.93
Site organization and management. Inflamm Bowel Dis (2005) 0.87
Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease. Intest Res (2016) 0.78